Venous Thrombosis

Cardiovascular
9
Pipeline Programs
7
Companies
8
Clinical Trials
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
6
Early DiscoveryClinical DevelopmentMarket

On Market (5)

Approved therapies currently available

U
APIXABANApproved
apixaban
Unknown Company
oral2020
Bristol Myers Squibb
ELIQUISApproved
apixaban
Bristol Myers Squibb
oral2025
Bristol Myers Squibb
ELIQUIS SPRINKLEApproved
apixaban
Bristol Myers Squibb
oral2025
U
RIVAROXABANApproved
rivaroxaban
Unknown Company
oral2025
J&
XARELTOApproved
rivaroxaban
Johnson & Johnson
Factor Xa Inhibitor [EPC]oral2011

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
3 programs
1
Long DOACPhase 41 trial
RivaroxabanN/A
RivaroxobanN/A
Active Trials
NCT04724460Completed179Est. Dec 2024
Bristol Myers Squibb
1 program
1
1
ApixabanPhase 2/31 trial
Active Trials
NCT00097357Completed1,238Est. Dec 2005
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
1
RivaroxabanPhase 31 trial
Active Trials
NCT00440193Completed3,449Est. Apr 2010
Pfizer
PfizerNEW YORK, NY
2 programs
1
PD 0348292Phase 21 trial
90ug levonorgestrel / 20 ug ethinyl estradiolN/A1 trial
Active Trials
NCT01297348Completed598,682Est. Apr 2012
NCT00306254Completed1,225Est. Jul 2007
Abbott
AbbottABBOTT PARK, IL
1 program
JETi lower extremity venous thrombosisN/A1 trial
Active Trials
NCT07027878Active Not Recruiting121Est. Aug 2025
Astellas
AstellasChina - Shenyang
1 program
The Risk of Venous Clotting in Patients After Renal TransplantN/A1 trial
Active Trials
NCT01413464Unknown120Est. Sep 2013
Sanofi
SanofiPARIS, France
1 program
Venous Thromboembolism Taskforce Audit ProgramN/A1 trial
Active Trials
NCT00535171Completed8,764

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerLong DOAC
Johnson & JohnsonRivaroxaban
Bristol Myers SquibbApixaban
PfizerPD 0348292
AbbottJETi lower extremity venous thrombosis
AstellasThe Risk of Venous Clotting in Patients After Renal Transplant
Pfizer90ug levonorgestrel / 20 ug ethinyl estradiol
SanofiVenous Thromboembolism Taskforce Audit Program

Clinical Trials (8)

Total enrollment: 613,778 patients across 8 trials

NCT04724460BayerLong DOAC

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

Start: Feb 2021Est. completion: Dec 2024179 patients
Phase 4Completed
NCT00440193Johnson & JohnsonRivaroxaban

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Start: Mar 2007Est. completion: Apr 20103,449 patients
Phase 3Completed
NCT00097357Bristol Myers SquibbApixaban

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Start: Oct 2004Est. completion: Dec 20051,238 patients
Phase 2/3Completed
NCT00306254PfizerPD 0348292

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Start: Mar 2006Est. completion: Jul 20071,225 patients
Phase 2Completed
NCT07027878AbbottJETi lower extremity venous thrombosis

JETi Lower Extremity Venous Thrombosis

Start: Mar 2020Est. completion: Aug 2025121 patients
N/AActive Not Recruiting
NCT01413464AstellasThe Risk of Venous Clotting in Patients After Renal Transplant

The Risk of Venous Clotting in Patients After Renal Transplant

Start: Mar 2011Est. completion: Sep 2013120 patients
N/AUnknown
NCT01297348Pfizer90ug levonorgestrel / 20 ug ethinyl estradiol

Study Of Lybrel In Relation To Venous Thromboembolism

Start: Jul 2007Est. completion: Apr 2012598,682 patients
N/ACompleted
NCT00535171SanofiVenous Thromboembolism Taskforce Audit Program

Venous Thromboembolism Taskforce Audit Program

Start: Jun 20078,764 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Physician Program Director, Los Angeles

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

J&J MedTech Neurovascular Senior Financial Analyst, R&D

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$79K - $128K/yr

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)